Every story we've covered involving corporate-strategy.
A few days after a disappointing capital-markets day raised questions about its near-term strategy, Danish pharmaceutical group Novo Nordisk agreed to a licensing arrangement valued at more than $1 billion. The announcement propelled shares of the unnamed Swedish partner sharply higher in trading.
No stories here yet.